Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

100.40 -1.44 (-1.41%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,567,534
Open 101.10
Bid (Size) 100.49 (1)
Ask (Size) 101.81 (1)
Prev. Close 101.84
Today's Range 100.31 - 101.76
52wk Range 62.41 - 105.69
Shares Outstanding N/A
Dividend Yield 1.76%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
Denmark's Health Minister, Sophie Lohde, has signaled the government's willingness to expand coverage for Novo Nordisk A/S's (NYSE: NVO) weight-loss drug Wegovy if the company shares some of the... 
Via Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga

Performance

YTD
+46.61%
+46.61%
1 Month
+2.78%
+2.78%
3 Month
+6.07%
+6.07%
6 Month
+23.55%
+23.55%
1 Year
+59.20%
+59.20%

More News

Read More
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Via Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Will NOVO-NORDISK A/S-SPONS ADR breakout?
Via Chartmill
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Via Talk Markets
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
Via The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Via The Motley Fool
Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases
Via Benzinga
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Watch the buy range for Li Auto, MongoDB, Novo Nordisk
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
Via The Motley Fool
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
Via Investor's Business Daily
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
Via Benzinga
Only Have $100? 3 No-Brainer Stocks to Buy Right Now
Via InvestorPlace
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
Via Benzinga
BellRing Brands gets pumped on the Ozempic weight-loss trend
Via MarketBeat
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
Via The Motley Fool
Google Leads Five S&P 500 Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Could Ozempic Harm These 3 Medical Device Stocks?
Via The Motley Fool
Novo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply Crunch
Via Benzinga
7 Stocks Set to Capitalize on the Coming Year-End Rally
Via InvestorPlace
$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.